Clinical Report: Extracellular Vesicles from Mesenchymal Stem Cells Influence Immune Responses in Sepsis
Overview
This study investigates the role of extracellular vesicles derived from induced pluripotent stem cell-derived mesenchymal stem cells (iMSC-EVs) in modulating immune responses in patients with surgical sepsis. Key findings indicate that specific cytokine profiles and patient characteristics are associated with 60-day mortality.
Background
Severe sepsis is a critical condition marked by dysregulated immune responses, leading to high mortality rates. Understanding the immune mechanisms involved in sepsis is essential for developing effective therapies.
Data Highlights
Factor
Association with Mortality
Age
Increased
Cancer Diagnosis
Increased
SOFA Score
Increased
IL-10
OR = 1.12
MCP-1
OR = 1.05
IL-10/TNF-α Ratio
OR = 6.61
Key Findings
Increased age, cancer diagnosis, and SOFA score were associated with higher mortality in sepsis patients.
Non-survivors had elevated levels of IL-10, MCP-1, and a higher IL-10/TNF-α ratio compared to survivors.
IL-10, MCP-1, and the IL-10/TNF-α ratio independently predicted 60-day mortality.
iMSC-EV treatment reduced LPS-induced inflammation and apoptosis in PBMCs from septic patients.
The IL-6/IL-10 ratio was lower in non-survivors.
Clinical Implications
The findings suggest that monitoring specific cytokine levels may aid in predicting mortality risk in sepsis patients. Additionally, iMSC-EVs could represent a promising therapeutic avenue for modulating immune responses in sepsis.
Conclusion
This study highlights the role of iMSC-EVs in influencing immune responses in sepsis.
